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S. aureus. Phylogenetic analysis showed that hand hygiene has a
direct impact on the clonality of MRSA hospital origin.
http://dx.doi.org/10.1016/j.ijid.2016.02.747
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Background: Inﬂuenza typically comprises a substantial por-
tion of acute respiratory infections, a leading cause of mortality
worldwide. However, inﬂuenza epidemiology data are lacking in
Egypt.Wedescribe sevenyearsofEgypt’s inﬂuenzahospitalizations
from a multi-site inﬂuenza surveillance system.
Methods & Materials: Syndromic case deﬁnitions identiﬁed
individuals with severe acute respiratory infection (SARI) admit-
ted to eight hospitals in Egypt. Standardized demographic and
clinical data were collected. Nasopharyngeal and oropharyngeal
swabs were tested for inﬂuenza using real-time reverse transcrip-
tion polymerase chain reaction and typed as inﬂuenza A or B, and
inﬂuenza A specimens subtyped.
Results: From November 2007–November 2014, 2,936/17,441
(17%) SARI cases were inﬂuenza-positive. Inﬂuenza-positive
patients were more likely to be older, female, pregnant, and have
chronic condition(s) (all p <0.05). Among them, 53 (2%) died, and
death was associated with older age, ﬁve or more days from symp-
tom onset to hospitalization, chronic condition(s), and inﬂuenza A
(all p <0.05). An annual seasonal inﬂuenza pattern occurred from
July–June. Each season, the proportion of the season’s inﬂuenza-
positive cases peaked during November–May (19–41%).
Conclusion: InEgypt, inﬂuenzahospitalizations cause consider-
able morbidity and mortality and its seasonality mirrors Northern
Hemisphere patterns. Additional assessment of inﬂuenza epidemi-
ology in Egypt may better guide disease control activities and
vaccine policy.
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Background: Fecal microbiome therapy (FMT) has become an
accepted rescue treatment for relapsing or recurring Clostridium
difﬁcile infection (CDI).While short-termeffectivenessof this treat-
ment approach is high, no data on the long-term efﬁcacy are
available.
Methods & Materials: From 17 patients (median age 84, range
55-93 years) who underwent 18 FMT procedures for relapsing or
recurring CDI long-term outcomes were analysed.
FMT was done via endoscopically placed jejunal tube using
500 ml (0.1 g/ml) of sterile prepared donor stool suspension from
healthy ﬁrst-degree relatives (n =15) or spouses (n =3).
Results: All patients had a Charlson comorbidity score >10
indicating multiple comorbidities. Median number of treatment
courses fot CDI before FMT was four (range 3-7). Postprocedure
efﬁcacy for FMT was 17/18 (94.4%). At day 30 14/18 (77.8%) were
without clinical symptomsor signsof relapse, byday1807/10 (70%)
were free from CDI, and after one year 6/9 (66.7%).
Leukocyte counts, albumin, clinical response measured by the
use of the Bristol Stool Chart (BSC) or stool lactoferrin at base-
line were not predictive for long-term response whereas a >75%
decrease after FMT in stool lactoferrin concentrations by day 7
compared to day 0 was indicative.
Conclusion: Even in elderly patients with severe or multiple
comorbidities andhigh risk of recurring CDI the use of FMTprotects
a substantial number of patients over more than one year.
The decrease in stool lactoferrin concentrations within one
week after FMT remained the only predictive biomarker for long-
term response in these patients.
http://dx.doi.org/10.1016/j.ijid.2016.02.749
